Background: According to the World Health Organization (WHO), approximately 70-95% of developing countries rely on traditional medicine, which includes around 365 plant, animal, and mineral-based preparations. Natural products consist of numerous biologically active compounds that exert effects against pathogens, making up about 25% of modern pharmaceuticals derived from plants. Since plants are a combination of various metabolites, they can have therapeutic effects, side effects, and toxicity in the human body. Based on the traditional use of medicinal herbs in Mongolian and Tibetan medicine for their sedative properties, we selected the medicinal herbs Valeriana officinalis L. and Leonurus sibiricus L., The objective is to develop new medicinal preparations that can be utilized in modern medical practice to treat, prevent, or supplement the treatment of depression and anxiety. Consequently, it is necessary to prepare a herbal complex from these selected plants and conduct studies to investigate their subchronic toxicity and sedative activities. Aim: To study subchronic and sedative activity of herbal complex preparations. Materials and Methods: The herbal complex preparation was prepared from the 70% ethanol extract of the roots of Valeriana officinalis L. and the aerial parts of Leonurus sibiricus L., and a compound preparation was made in a 30:70 ratio. Subchronic toxicity study was conducted on Wistar rats weighing 180-250 g according to the OECD-407 guidelines. The sedative activity of herbal complex preparation was studied on C57BL/6 and BALB/c mice using the dark/light transition test according to Takao K., and the hole-board test according to Hiroshi Takeda. Results: In the sub-chronic toxicity study of the herbal complex preparation, biochemical analysis of the serum (including ALT, AST, creatinine, and urea) and histopathological examination of the liver, kidney, and heart showed no statistically significant changes when comparing the experimental groups to the control group. The herbal complex preparation at a dose of 1000 mg/kg increased the time spent in the dark area, decreased the time spent in the light area, and the number of transitions between the two areas of mice in the dark/light transition test, and reduced the number of head-dipping into the holes of mice in the hole-board test. Conclusion The herbal complex preparation exhibited low toxicity at doses of 1000 mg/kg and 1500 mg/kg based on biochemical and histopathological examinations in the subchronic toxicity study. Furthermore, the preparation demonstrated sedative effects at a dose of 1000 mg/kg.

Background: Urinary tract infections (UTIs) are common, affecting 150 million people worldwide annually. It is estimated that 1% of the population suffers from urinary tract infections. The most common infections in kidney and urinary tract are Escherichia coli, Staphylococcus saprophyticus, Klebsiella, Enterobacter and Proteus which account 80%, 5-15% and 5-10%, respectively. Oxidative stress, inflammation, and apoptosis are critical factors involved in the pathogenesis of kidney disease. Oxidative stress, a pathological condition characterized by an imbalance between reactive oxygen species (ROS) and the body’s antioxidant defenses, leads to cellular damage and is directly implicated in the initiation and progression of acute kidney injury. Antioxidants serve a protective role by mitigating the harmful effects of free radicals and oxidative stress on cellular structures. Drawing upon the extensive resources of medicinal plants and the therapeutic practices of traditional medicine, plants rich in antioxidant compounds, including Dasiphora fruticosa (L.), Cynara scolymus (L.), and Rosa acicularis (L.), were selected for the development of the Phytonephro-SAN preparation. The phytochemical profile and nephroprotective properties of these plants have been investigated and validated. Moving forward, further studies are warranted to assess the safety profile of the formulation, including comprehensive toxicity evaluations. Aim: To investigate and establish the subacute toxicity and antibacterial activity of the Phytonephro-SAN preparation. Materials and Methods: The subacute toxicity assessment of the Phythonephro-SAN preparation was conducted on Wistar rats following the OECD-407 guidelines. The study of the antibacterial activity of the preparation was determined by the broth dilution method. Results: The subacute toxicity assessment, evaluated through parameters such as body and organ weights and complete blood count (CBC), revealed no statistically significant differences between the groups administered the Phytonephro-SAN preparation at doses of 500 mg/kg and 1000 mg/kg, and the control group. According to the study of antibacterial activity, Phytonephro-SAN preparation has antibacterial activity at 90 mg/ml and 80 mg/ml doses. Conclusion The administration of the Phytonephro-SAN preparation to Wistar rats at doses of 500 mg/kg and 1000 mg/kg over 28 days did not result in mortality, and no significant changes were observed in body and organ weights or CBC parameters. These findings support the conclusion that the preparation possesses minimal toxicity. Additionally, the preparation demonstrated effective antibacterial activity against specific urinary tract pathogens at higher concentrations.